Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial

• DOI: 10.1016/j.xcrm.2023.101025
• Publication Date: 2023-05-02T21:42:06Z
• Authors: Tulika Ranjan; Soma Sengupta; Michael J. Glantz; Richard M. Green; Alexander Yu; Dawit Aregawi; Rekha Chaudhary; Ricky Chen; Mario Zuccarello; Christine Lu-Emerson; Hugh D. Moulding; Neil Belman; Jon Glass; Aaron Mammoser; Mark Anderson; Jagan Valluri; Nicholas Marko; Jason Schroeder; Steven Jubelirer; Frances Chow; Pier Paolo Claudio; Anthony M. Alberico; Seth T. Lirette; Krista L. Denning; Candace M. Howard
• Keywords: cancer stem cells; Brain Neoplasms; overall survival; glioblastoma; drug response assay; Antineoplastic Agents; personalized medicine; chemotherapy; Article; 3. Good health; Treatment Outcome; Neurology; Oncology; assay-guided chemotherapy; Medicine and Health Sciences; Neoplastic Stem Cells; Humans; Surgery; ChemoID; Glioblastoma; functional assay; recurrent glioblastoma

Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors.In randomized trial (NCT03632135), assay, personalized approach selecting most effective treatment from FDA-approved chemotherapies, improves survival rGBM (2016 WHO classification) over physician-chosen chemotherapy. In assay-guided group, median 12.5 months (95% confidence interval [CI], 10.2–14.7) compared 9 CI, 4.2–13.8) physician-choice group (p = 0.010) as per interim efficacy analysis. The has significantly lower risk death (hazard ratio [HR] 0.44; 95% 0.24–0.81; p 0.008). Results this study offer promising way provide more affordable socioeconomic groups US and around world.